文献速递肝病

利用常用生物标志物改进普通人群10年严重肝病风险预测

Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers.
PubMed 文献 · Aliment Pharmacol Ther · 2022-12-25

在瑞典斯德哥尔摩126,925名35-79岁健康体检者中,利用全国登记系统确定10年严重肝病累积发生率,平均随访9.3年共630例(0.5%)。年龄、FIB-4评分、糖尿病或血糖异常及γ-谷氨酰转移酶是分类风险最重要的特征,据此识别出24组10年累积发生率从0.2%到32.1%不等的人群。

要点

  • 年龄、FIB-4评分、糖尿病或血糖异常及γ-谷氨酰转移酶是分类严重肝病风险最重要的特征。
  • 据此识别24组人群,10年严重肝病累积发生率从0.2%到32.1%不等。
  • 在FIB-4评分基础上加入年龄和特定常用生物标志物可大幅改进风险识别。

核心结论

  • 在普通人群中利用FIB-4评分识别严重肝病风险升高的个体,可通过加入年龄和初级保健机构常用的特定生物标志物而大幅改进。

研究设计与样本

  • 利用瑞典斯德哥尔摩1985至1996年接受健康体检的126,925名35-79岁个体的实验室和临床数据。
  • 使用瑞典全国登记系统确定10年严重肝病累积发生率,严重肝病为肝硬化和其并发症诊断的复合终点。

主要发现

  • 平均随访9.3年期间,确定630例新发严重肝病(0.5%)。
  • 年龄、FIB-4评分、糖尿病或血糖异常及γ-谷氨酰转移酶是分类风险特征最重要的因素。
  • 识别出24组人群,10年严重肝病累积发生率从0.2%(年龄35-65岁、低FIB-4、无糖尿病或血糖异常且γ-谷氨酰转移酶正常)到32.1%(年龄35-65岁、高FIB-4、糖尿病或血糖异常且γ-谷氨酰转移酶高)。

关键数值与推荐

  • 低风险组:年龄35-65岁、低FIB-4、无糖尿病或血糖异常且γ-谷氨酰转移酶正常,10年严重肝病累积发生率0.2%。
  • 高风险组:年龄35-65岁、高FIB-4、糖尿病或血糖异常且γ-谷氨酰转移酶高,10年严重肝病累积发生率32.1%。

临床怎么用

  • 作者认为,这些参数应考虑纳入未来风险预测模型的开发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estimating the risk for cirrhosis in the general population is complex. Existing prediction tools are in general unsatisfactory. AIMS: To explore if using commonly available biomarkers can improve the commonly used FIB-4 score in the identification of subgroups at risk of cirrhosis. METHODS: We used laboratory and clinical data on 126,925 individuals aged 35-79 years in Stockholm, Sweden, undergoing health examinations from 1985 to 1996. We used Swedish nationwide registries to ascertain 10-year cumulative incidence of severe liver disease, a composite of diagnoses corresponding to cirrhosis and its complications. We considered combinations of biomarkers associated with severe liver disease to identify subgroups with different risk profiles. RESULTS: During an average follow-up of 9.3 years, we ascertained 630 incident cases of severe liver disease (0.5%). Age, the FIB-4 score, diabetes or impaired glucose and gamma-glutamyl transferase (gGT) were the most relevant characteristics for classifying risk profiles. Using these factors, we identified 24 groups with a cumulative incidence of severe liver disease at 10 years ranging from 0.2% (age 35-65, low FIB-4, no diabetes or impaired glucose and normal gGT) to 32.1% (age 35-65, high FIB-4, diabetes or impaired glucose and high gGT). CONCLUSIONS: Identification of subjects at increased risk of severe liver disease in the general population using the FIB-4 score can be substantially improved by adding age and specific biomarkers commonly available in the primary care setting. These parameters should be considered for inclusion in the development of future risk prediction models.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Hagström H, Yan J, Talbäck M, et al. Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers. Aliment Pharmacol Ther. 2022. PMID: 36566508. doi:10.1111/apt.17374

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。